Navigation Links
Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
Date:8/28/2007

w.sec.gov.

Additional Information and Where to Find It

This news release may be deemed to be solicitation material in respect of the proposed acquisition of PolyMedica by Medco. In connection with the proposed acquisition, Medco and PolyMedica intend to file relevant materials with the SEC, including PolyMedica's proxy statement on Schedule 14A. SHAREHOLDERS OF POLYMEDICA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING POLYMEDICA'S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents free of charge at the SEC's web site, http://www.sec.gov, and PolyMedica shareholders will receive information at an appropriate time on how to obtain transaction-related documents for free from PolyMedica. Such documents are not currently available.

Medco and its directors and executive officers, and PolyMedica and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the holders of PolyMedica common stock in respect of the proposed transaction. Information about the directors and executive officers of Medco is set forth in its proxy statement for its 2007 Annual Meeting of Shareholders, which was filed with the SEC on April 16, 2007. Information about the directors and executive officers of PolyMedica is set forth in its proxy statement for its 2007 Annual Meeting of Shareholders, which was filed with the SEC on July 27, 2007. Investors may obtain additional information regarding the interest of such participants by reading the proxy statement regarding the acquisition when it becomes available.

Table

Selected Information

(Unaudited)

(In millions, except for per-share data)

12 Months Ended December 30, 2006 ME
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience ... human vision system, announced today a partnership with eight-time All-Star, ... Paul to develop a new mobile app designed for ... real-life on-court performance. Vision is the inception of ... a ball or blocking a pass. The critical impact vision ...
(Date:8/26/2015)... Manhattan, KS (PRWEB) , ... August 26, 2015 ... ... & Biologic Solutions, announces today that a second US laboratory is to open ... in accordance with the continued partnership and long-term growth of research and development ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Calif., Feb. 2 IPC The Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician group ... Conference held in Naples, FL. , , ... Speaker: ... Date: ...
... SAN DIEGO, Feb. 2 BioMed Realty Trust, Inc. (NYSE: ... for its fourth quarter and year ended December 31, 2008 ... D. Gold, Chairman and Chief Executive Officer, and Kent Griffin, ... call at 10:00 a.m. Pacific Time on Thursday, February 12, ...
... Cancer Advances, Inc. (Cancer Advances), a Cato BioVentures ... acquisition of all the technology and intellectual property for ... for application in three gastrointestinal cancers. Cancer Advances was ... to acquire products developed to inhibit the hormone, gastrin, ...
Cached Biology Technology:IPC The Hospitalist Company, Inc. to Present at Deutsche Bank 2009 Small and Mid Cap Conference 2BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results 2Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers 2Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers 3
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... When forest biologist Claire Williams boards ferries bound for North ... coast, ferry captains call her the "Pollen Lady." ... forth from the islands to the mainland, collecting pine pollen ... from the loblolly pine the most commonly planted tree ...
... are often hamstrung by less-than-ideal grafting material when performing ... or cancer. Conventional synthetic bone grafts are typically made ... conform to the complex and irregular shapes that often ... fixation devices that require open surgeries to insert and ...
... -- Highly dangerous Cryptococcus fungi love sugar and ... particular, they thrive on a sugar called inositol ... To borrow inositol from a person,s brain, the fungi ... transporter molecules. While a typical fungus has just two such ...
Cached Biology News:Gone with the wind: Far-flung pine pollen still potent miles from the tree 2Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers 2This is your brain on Cryptococcus: Pathogenic fungus loves your brain sugar 2
... Studio Enterprise is integrated informatics solution ... mechanisms and drug response modeling. This ... worlds largest knowledge base of biological ... MedScan module capable of extracting pathway-related ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... Preparation Note: Prepared by a modification ... et al., Biotechnol. Bioeng., ... One unit will yield an A ... ml of water (1 cm light ...
Biology Products: